Market Overview

US Drug Watchdog Now Urges Victims Of A Transvaginal Mesh,Tape, or Sling Failure To Call Them For The Names Of The Best Women Attorneys-No Other Group Offers This Service


The US Drug Watchdog says, "We are now calling transvaginal mesh, tape, or sling failures the absolute worst mess we have ever seen for women, and the damages are literally impossible to even comprehend. We are certain we are also talking about thousands of US women. According to the New York Times, in 2010, about 185,000 women underwent procedures in which mesh was implanted vaginally to treat urinary incontinence. That was 2010 alone." Transvaginal mesh failure occurs when the mesh fails to bind to a woman's pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. This complication is more commonly referred to as "erosion." Erosion may result in extreme pain, infection, bleeding, vaginal discharge, with no possibility for sexual intercourse. The group is urging any woman, who has had the transvaginal mesh, tape, or sling surgical procedure done, and now has developed severe medical complications to call them anytime at 866-714-6466. As part of its initiative the US Drug Watchdog is offering to send all US women, who are victims of a transvaginal mesh, tape, or sling failure to national caliber attorneys-who are all women. http://USDrugWatchdog.Com

(PRWEB) October 26, 2012

The US Drug Watchdog has launched a very aggressive national initiative focused on identifying all women recipients of a transvaginal mesh, tape, or sling, who are now severely damaged by this type of product. Transvaginal mesh products were designed for women, who were suffering from pelvic organ prolapse, and stress urinary incontinence. Initially the US FDA called the procedure to install a transvaginal mesh, tape, or sling-minimally-invasive. According to court records, women who experience a transvaginal mesh failure may need to have numerous corrective surgeries, IV therapy, blood transfusions and drainage of hematomas or abscesses. The US Drug Watchdog is offering to help all US women, who are now victim's of a transvaginal mesh, sling, or tape failure get to the best possible attorneys, and the group is promising the attorneys at least initially will all be women. For more information victims of a Transvaginal Mesh failure are urged to contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com

The US Drug Watchdog is indicating symptoms of a vaginal mesh, tape, or sling failure may include:

  • Pain during sexual intercourse caused by erosion.
  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Vaginal Bleeding
  • Vaginal Infection
  • Urinary problems
  • Organ perforation

The US Drug Watchdog says, "One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures involving medical devices like the transvaginal mesh, tape, or a sling. If you have a friend, or loved one who is a recipient of a transvaginal mesh, sling, or tape that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain all transvaginal mesh, tape, or sling victims get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal, and we will do our absolute best to make certain all of the attorneys are initially women." http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multi District litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:
C.R. Bard, Inc., (MDL No. 2187);
American Medical Systems Inc., MDL No. 2325);
Boston Scientific Corp., (MDL No. 2326); and Johnson & Johnson's Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit:

View Comments and Join the Discussion!